DPP-IV inhiibiitor-associaiatedd arthraalgiaias

Endocrine Practice

Volumn 19, Issue 2, 2013, Pages 377-

  Chaicha Brom, Tira ^a   Yasmeen, Tahira ^b  

^a Section of Endocrinology Diabetes and Metabolism   (United States)

^b ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTHRALGIA; CARPOMETACARPAL JOINT; CASE REPORT; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; LETTER; MALE; MORNING STIFFNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; RASH; T LYMPHOCYTE; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DAILY LIFE ACTIVITY; DRUG COMBINATION; DRUG MONITORING; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ARTHRALGIA; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAZOLES;

EID: 84877132246     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
2. Schnyder, B. Approach to the patient with drug allergy. Med Clin North Am. 2010;94:665-679.
3. Yamauchi K, Sato Y, Yamashita K. RS3PE in Association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care. 2012;35:e7.